Platform Technology to Fight Autoimmune Disease

Changing T Cell Activation with Recombinant T Cell Receptor Ligands

MHC II molecules present antigenic peptides to T cells. T cell activation by MHC II molecules results in release of inflammatory factors that cause autoimmune disease.

Artielle's Recombinant T Cell Receptor Ligands (RTLs) can be made to present different antigens to T Cells and lack the CD4 binding domain of MHC II molecules.

T cell activation by RTLs results in the release of anti-inflammatory factors that may reduce autoimmune disease symptoms.